Total Artificial Heart
| dc.contributor.author | Elsaeiti, Sajedah | |
| dc.contributor.author | Hamouda, Yomna | |
| dc.contributor.author | Eloriby, Doaa | |
| dc.contributor.author | Elmesmari, Shahed | |
| dc.date.accessioned | 2021-02-28T11:19:52Z | |
| dc.date.available | 2021-02-28T11:19:52Z | |
| dc.date.issued | 2021-02-28 | |
| dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/2788 | |
| dc.description | Heart transplantation remains the gold standard treatment for endstage heart failure. The Total Artificial Heart (TAH) is the only Food and Drug Administration (FDA) approved artificial heart used for bridging patients to transplantation. Outcomes in patients who undergo implantation of the TAH at experienced centers have been good and reproducible. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Faculty of Pharmacy | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title | Total Artificial Heart | en_US |
| dc.type | Presentation | en_US |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Attribution 3.0 United States